Fortress Biotech (FBIO) Gross Margin (2015 - 2026)

Fortress Biotech's Gross Margin history runs 11 years deep, the most recent figure standing at 61.3% for Q4 2025.

• In Q4 2025, Gross Margin fell 783.0% year-over-year to 61.3%; the TTM figure through Dec 2025 stood at 65.03% (up 121.0% YoY), while the FY2025 annual figure was 65.83%, up 203.0% from the prior year.
• Gross Margin for Q4 2025 stood at 61.3%, down from 67.36% in the prior quarter.
• The five-year high for Gross Margin was 113.43% in Q4 2022, with the low at 4728.39% in Q2 2021.
• The 5-year median for Gross Margin is 59.72% (2022), against an average of 747.75%.
• The sharpest annual moves came in 2021 and 2022: Gross Margin tumbled 479535 bps in 2021, then surged 478653 bps in 2022.
• Fortress Biotech's Gross Margin stood at 83.71% in 2021, then soared by 35 bps to 113.43% in 2022, then dropped by 25 bps to 85.27% in 2023, then decreased by 19 bps to 69.13% in 2024, then slipped by 11 bps to 61.3% in 2025.
• Business Quant data shows FBIO's Gross Margin at 61.3% in Q4 2025, 67.36% in Q3 2025, and 67.09% in Q2 2025.